Showing 691-700 of 867 results for "".
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management
- Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of Investigational Treatment for MGDhttps://modernod.com/news/azura-ophthalmics-announces-positive-topline-results-from-phase-2-program-of-the-companys-investigational-treatment-for-mgd/2478934/Azura Ophthalmics announced topline results from a phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). AZR-MD-001 met its primary endpoints showing improvements in signs and symptoms of MGD, reaching statistical significance com
- Breakthrough by Moran Eye Center Scientist, Colleagues Fuels New Line of Disease Researchhttps://modernod.com/news/breakthrough-by-moran-eye-center-scientist-colleagues-fuels-new-line-of-disease-research/2478830/Scientists like the John A. Moran Eye Center’s Paul S. Bernstein, MD, PhD, know a special class of lipids, or fatty acids, found in the retina of the eye and in just a few other parts of the body play an important role in maintaining vision. But it’s been difficult to study whether giving
- Volk Optical Releases ClearPod to Address Mask-Related Fogging During Fundus Examinationshttps://modernod.com/news/volk-optical-releases-clearpod-to-address-mask-related-fogging-during-fundus-examinations/2478724/Volk Optical announced the release their newest product, the ClearPod, which aims to solve the problem of mask-related fogging during fundus examinations. This patent-pending design has been created in collaboration with ophthalmologists Bradley Sacher, MD, a cataract specialist, and Jerem
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/Azura Ophthalmics announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significan
- Kerry Solomon First in US to Implant Alcon’s Vivity IOLhttps://modernod.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/Kerry Solomon, MD, partner at Carolina Eyecare Physicians, Charleston, South Carolina, is the first in the United States following FDA approval to complete surgery using Alcon’s AcrySof IQ Vivity Extended Range of Vision IOL, according to a news release. “The Vivity lens is a remarka
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi